Akebia Therapeutics, Inc.
$1.10
The Read: Historically, Akebia Therapeutics (AKBA) has experienced median absolute price moves of about 12% around key catalysts, with notable outsized declines of ~18% and ~20% following earnings misses and disappointing commercial guidance despite some positive product launch metrics and pipeline progress, while avoiding dilution risks has led to modest ~3% gains within expected ranges.
Price
Overlays
Panel
AKBA
Hover to view data
No Data